Harnessing the Therapeutic Potential of Peptides for Synergistic Treatment of Alzheimer's Disease by Targeting Aβ Aggregation, Metal-Mediated Aβ Aggregation, Cholinesterase, Tau Degradation, and Oxidative Stress.

Alzheimer's disease (AD) is a progressive multifaceted neurodegenerative disease and remains a formidable global health challenge. The current medication for AD gives symptomatic relief and, thus, urges us to look for alternative disease-modifying therapies based on a multitarget directed approach. Looking at the remarkable progress made in peptide drug development in the last decade and the benefits associated with peptides, they offer valuable chemotypes [multitarget directed ligands (MTDLs)] as AD therapeutics. This review recapitulates the current developments made in harnessing peptides as MTDLs in combating AD by targeting multiple key pathways involved in the disease's progression. The peptides hold immense potential and represent a convincing avenue in the pursuit of novel AD therapeutics. While hurdles remain, ongoing research offers hope that peptides may eventually provide a multifaceted approach to combat AD.

• Publication year

  2024

• Venue

  ACS Chemical Neuroscience

• Publication date

  2024-07-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acschemneuro.4c00246PMID 38979773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amyloid Targeting Red Emitting AIE Dots for Diagnostic and Therapeutic Application against Alzheimer's Disease.

  2024cited by this paper
• 2024 Alzheimer's disease facts and figures

  2024cited by this paper
• Acetylcholinesterase: A Versatile Template to Coin Potent Modulators of Multiple Therapeutic Targets

  2024cited by this paper
• Nanomodulators That Target Alzheimer’s Disease: A Review

  2024cited by this paper
• Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer's Disease Therapy.

  2024cited by this paper
• Synthesis and mechanistic study of ultrashort peptides that inhibits Alzheimer's Aβ-aggregation-induced neurotoxicity.

  2024cited by this paper
• Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway.

  2024cited by this paper
• A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.

  2024cited by this paper
• A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease

  2024cited by this paper
• Redox changes and cellular senescence in Alzheimer's disease

  2024cited by this paper
• Rationally Designed Cu(I) Ligand to Prevent CuAβ-Generated ROS Production in the Alzheimer's Disease Context.

  2024cited by this paper
• Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment.

  2024cited by this paper
• Reactive oxygen species in biological systems: Pathways, associated diseases, and potential inhibitors—A review

  2023cited by this paper
• Mitochondrial calcium function is altered by lithium in hippocampal cell culture and triple transgenic for Alzheimer’s disease

  2023cited by this paper
• Neurotropic virus infection and neurodegenerative diseases: Potential roles of autophagy pathway

  2023cited by this paper
• Bifunctional backbone modified squaramide dipeptides as amyloid beta (Aβ) aggregation inhibitors.

  2023cited by this paper
• Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy

  2023cited by this paper
• The Role of Traditional Chinese Medicine Natural Products in β-Amyloid Deposition and Tau Protein Hyperphosphorylation in Alzheimer’s Disease

  2023cited by this paper
• A Molecular Integrative Study on the Inhibitory Effects of WRR and ERW on Amyloid β Peptide (1–42) Polymerization and Cell Toxicity

  2023cited by this paper
• Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease

  2023cited by this paper
• The amyloid-β peptide: Guilty as charged?

  2023cited by this paper
• Exploring Multitarget Strategies for Membrane Protection in Alzheimer's Disease.

  2023cited by this paper
• Site‐specific phosphorylation of tau impacts mitochondrial function and response to stressors

  2023cited by this paper
• Metal Binding of Alzheimer’s Amyloid-β and Its Effect on Peptide Self-Assembly

  2023cited by this paper
• Pathogenesis of Alzheimer's Disease and Diversity of 1,2,3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential.

  2023cited by this paper
• Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging

  2023cited by this paper
• Role of neuroinflammation in neurodegeneration development

  2023cited by this paper
• Mitochondrial dysfunction and oxidative stress in Alzheimer's disease, and Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis -An updated review.

  2023cited by this paper
• Triazole-Peptide Conjugate as a Modulator of Aβ-Aggregation, Metal-Mediated Aβ-Aggregation, and Cytotoxicity.

  2023cited by this paper
• A tailored tetravalent peptide displays dual functions to inhibit amyloid β production and aggregation

  2023cited by this paper
• Inhibition of Human Cholinesterases and in vitro β‐Amyloid Aggregation by Rationally Designed Peptides

  2023cited by this paper
• Aβ-oligomers: A potential therapeutic target for Alzheimer's disease.

  2023cited by this paper
• The therapeutic potential of carnosine: Focus on cellular and molecular mechanisms

  2023cited by this paper
• Research progress of natural products and their derivatives against Alzheimer’s disease

  2023cited by this paper
• Controlling Amyloid Beta Peptide Aggregation and Toxicity by Protease-Stable Ligands

  2023cited by this paper
• Hallmarks of neurodegenerative diseases.

  2023cited by this paper
• The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview

  2023cited by this paper
• Multivalent Nanobody Conjugate with Rigid, Reactive Oxygen Species Scavenging Scaffold for Multi‐Target Therapy of Alzheimer's Disease

  2023cited by this paper
• Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer’s Disease: Experimental and Computational Insights

  2023cited by this paper
• Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models

  2022cited by this paper
• Bi-Directional Relationship Between Autophagy and Inflammasomes in Neurodegenerative Disorders

  2022cited by this paper
• KLVFF oligopeptide-decorated amphiphilic cyclodextrin nanomagnets for selective amyloid beta recognition and fishing.

  2022cited by this paper
• Lecanemab in Early Alzheimer's Disease.

  2022cited by this paper
• The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators.

  2022cited by this paper
• Advanced nanomaterials for modulating Alzheimer's related amyloid aggregation

  2022cited by this paper
• Role of calcium dysregulation in Alzheimer's disease and its therapeutic implications

  2022cited by this paper
• Mechanistic insights into the mitigation of Aβ aggregation and protofibril destabilization by a D-enantiomeric decapeptide rk10.

  2022cited by this paper
• Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer’s Disease?

  2022cited by this paper
• Copper chelating cyclic peptidomimetic inhibits Aβ fibrillogenesis.

  2022cited by this paper
• Short Peptoid Evolved from the Key Hydrophobic Stretch of Amyloid-β42 Peptide Serves as a Potent Therapeutic Lead of Alzheimer's Disease.

  2022cited by this paper
• Therapeutic peptides: current applications and future directions

  2022cited by this paper
• Conformational-specific self-assembled peptides as dual-mode, multi-target inhibitors and detectors for different amyloid proteins.

  2022cited by this paper
• Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases

  2021cited by this paper
• New approaches to symptomatic treatments for Alzheimer’s disease

  2021cited by this paper
• Rational Design of a Cu Chelator That Mitigates Cu‐Induced ROS Production by Amyloid Beta

  2021cited by this paper
• The biological activities of butyrylcholinesterase inhibitors.

  2021cited by this paper
• Age-related changes in tau and autophagy in human brain in the absence of neurodegeneration

  2021cited by this paper
• The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA

  2021cited by this paper
• Targeting oxidative stress in disease: promise and limitations of antioxidant therapy

  2021cited by this paper
• Multifunctional peptide-assembled micelles for simultaneously reducing amyloid-β and reactive oxygen species†

  2021cited by this paper
• Tau/Aβ chimera peptides: a Thioflavin-T and MALDI-TOF study of Aβ amyloidosis in the presence of Cu(II) or Zn(II) ions and Total Lipid Brain Extract (TLBE) vesicles.

  2021cited by this paper
• Novel Peptide-Calix[4]arene Conjugate Inhibits Aβ Aggregation and Rescues Neurons from Aβ’s Oligomers Cytotoxicity In Vitro

  2021cited by this paper
• Alzheimer's disease and its treatment by different approaches: A review.

  2021cited by this paper
• Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

  2021cited by this paper
• Molecular mechanism of Autophagy: Its role in the therapy of Alzheimer's disease.

  2020cited by this paper
• Tau/Aβ chimera peptides: Evaluating the dual function of metal coordination and membrane interaction in one sequence.

  2020cited by this paper
• Conjugation of RTHLVFFARK to human lysozyme creates a potent multifunctional modulator for Cu2+-mediated amyloid β-protein aggregation and cytotoxicity.

  2020cited by this paper
• A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

  2020cited by this paper
• Amyloid β-protein and beyond: the path forward in Alzheimer's disease.

  2020cited by this paper
• Current understanding of metal ions in the pathogenesis of Alzheimer’s disease

  2020cited by this paper
• Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease

  2020cited by this paper
• Helical γ-peptide foldamers as dual inhibitors of amyloid-β peptide and islet amyloid polypeptide oligomerization and fibrillization.

  2020cited by this paper
• Identification and molecular docking study of fish roe-derived peptides as potent BACE 1, AChE, and BChE inhibitors.

  2020cited by this paper
• Rhodamine-Based Metal Chelator: A Potent Inhibitor of Metal-Catalyzed Amyloid Toxicity

  2020cited by this paper
• Human Serum Albumin-Inspired Glycopeptide-Based Multifunctional Inhibitor of Amyloid-β Toxicity

  2020cited by this paper
• Hyaluronan-carnosine conjugates inhibit Aβ aggregation and toxicity

  2020cited by this paper
• Ageing as a risk factor for neurodegenerative disease

  2019cited by this paper
• Natural products and their derivatives as multifunctional ligands against Alzheimer's disease

  2019cited by this paper
• Peptide‐Based Molecular Strategies To Interfere with Protein Misfolding, Aggregation, and Cell Degeneration

  2019cited by this paper
• Small Molecule Inhibits Metal-Dependent and -Independent Multifaceted Toxicity of Alzheimer's Disease.

  2019cited by this paper
• Potential Neuroprotective Peptide Emerged from Dual Neurotherapeutic Targets: A Fusion Approach for the Development of Anti-Alzheimer's Lead.

  2019cited by this paper
• d-Enantiomeric RTHLVFFARK-NH2: A Potent Multifunctional Decapeptide Inhibiting Cu2+-Mediated Amyloid β-Protein Aggregation and Remodeling Cu2+-Mediated Amyloid β Aggregates.

  2019cited by this paper
• In silico Approach for Designing Potent Neuroprotective Hexapeptide.

  2019cited by this paper
• A Comprehensive Review on Current Advances in Peptide Drug Development and Design

  2019cited by this paper
• Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease

  2018cited by this paper
• Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.

  2018cited by this paper
• Pharmacodynamics in Alzheimer's disease model rats of a bifunctional peptide with the potential to accelerate the degradation and reduce the toxicity of amyloid β-Cu fibrils.

  2018cited by this paper
• Design of nonapeptide LVFFARKHH: A bifunctional agent against Cu2+‐mediated amyloid β‐protein aggregation and cytotoxicity

  2018cited by this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cited by this paper
• Designing a new multifunctional peptide for metal chelation and Aβ inhibition.

  2018cited by this paper
• Discovery of Neuroregenerative Peptoid from Amphibian Neuropeptide That Inhibits Amyloid-β Toxicity and Crosses Blood-Brain Barrier.

  2018cited by this paper
• Impact of nanoparticles on amyloid peptide and protein aggregation: a review with a focus on gold nanoparticles.

  2018cited by this paper
• Inflammation as a central mechanism in Alzheimer's disease

  2018cited by this paper
• Genesis of Neuroprotective Peptoid from Aβ30-34 Inhibits Aβ Aggregation and AChE Activity.

  2018cited by this paper
• Carnosine-LVFFARK-NH2 Conjugate: A Moderate Chelator but Potent Inhibitor of Cu2+-Mediated Amyloid β-Protein Aggregation.

  2018cited by this paper
• Chelating and antioxidant properties of l-Dopa containing tetrapeptide for the treatment of neurodegenerative diseases.

  2018cited by this paper
• Mitochondria and Alzheimer’s Disease: the Role of Mitochondrial Genetic Variation

  2018cited by this paper
• RTHLVFFARK-NH2: A potent and selective modulator on Cu2+-mediated amyloid-β protein aggregation and cytotoxicity.

  2018cited by this paper
• Studies of the Process of Amyloid Formation by Aβ Peptide

  2018cited by this paper
• Autophagy and Alzheimer’s Disease: From Molecular Mechanisms to Therapeutic Implications

  2018cited by this paper

• Chiral pool approach in design, synthesis, characterization, and evaluation of novel levorotatory- 1, 2, 4-triazole peptide-like AChE inhibitors

  2026cites this paper
• Mutations in the Aβ42 Recognition Sequence KLVFF Afford New Pentapeptide Inhibitors of Aβ42 Fibrillation: Computation-Driven Rational Design and Experimental Validation.

  2026cites this paper
• Delineating the tryptophan-galactosylamine conjugate mediated structural distortions in Aβ42 protofibrils.

  2025cites this paper
• Green procedures for synthesizing potential hNMDA receptor allosteric modulators through reduction and one-pot reductive acetylation of nitro(hetero)arenes using a superparamagnetic Fe3O4@APTMS@Cp2ZrClx (x = 0, 1, 2) nanocatalyst

  2025cites this paper
• Tripeptides inhibit dual targets AChE and BACE-1: a computational study

  2025cites this paper
• Therapeutic and clinical potential of thiolutin microneedles on Alzheimer's disease mitigation.

  2025cites this paper
• The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid‐β, Oxidative Stress, and Neuroinflammation

  2025cites this paper
• Astaxanthin Suppresses Amyloid-Beta-Induced Toxicity in AD Transgenic Caenorhabditis elegans via Promoting Skn-1-Dependent Proteasomal Activity.

  2025cites this paper
• Biological evaluation and molecular Docking studies of the prepared chalcone derivatives as potential anti-Alzheimer agents

  2025cites this paper
• The Synergistic Potential of Rationally Designed Phenol-Triazole Derivatives to Attenuate Aβ/Cu2+-Aβ Aggregation and Reactive Oxygen Species.

  2025cites this paper
• Donepezil-based rational design of N-substituted quinazolinthioacetamide candidates as potential acetylcholine esterase inhibitors for the treatment of Alzheimer's disease: in vitro and in vivo studies.

  2025cites this paper
• Bifunctional BODIPY-Clioquinol Copper Chelator with Multiple Anti-AD Properties

  2025cites this paper
• Biochemometric-guided isolation of new Isosteroidal alkaloids from Fritillaria cirrhosa D.Don (Liliaceae, syn. Fritillaria roylei Hook) as acetylcholinesterase inhibitors.

  2024cites this paper
• Hybrid Metal Catalysts as Valuable Tools in Organic Synthesis: An Overview of the Recent Advances in Asymmetric C─C Bond Formation Reactions

  2024cites this paper